EDWARDS LIFESCIENCES CORPORATION (NYSE:EW) Files An 8-K Other Events

ME Staff 8-k
-
0

EDWARDS LIFESCIENCES CORPORATION (NYSE:EW) Files An 8-K Other Events
Item 8.01 Other Events.

On May29, 2018, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), filed with the Securities and Exchange Commission a prospectus supplement (the “Prospectus Supplement”) to the prospectus dated August29, 2016, which was included in the Company’s automatic shelf registration statement on FormS-3 (No.333-213358). The Prospectus Supplement relates to the resale from time to time of up to 252,497 shares of the Company’s common stock, $1.00 par value per share, by the stockholders named therein.

In connection with the filing of the Prospectus Supplement, the Company is filing an opinion of its counsel, O’Melveny& Myers LLP, regarding the legality of the common stock being registered, which opinion is attached as Exhibit5.1 to this Current Report on Form8-K.

Item 8.01 Financial Statements and Exhibits.

(d)Exhibits


Edwards Lifesciences Corp Exhibit
EX-5.1 2 a18-14368_3ex5d1.htm EX-5.1 Exhibit 5.1     O’Melveny & Myers LLP T: +1 949 823 6900 610 Newport Center Drive F: +1 949 823 6994 17th Floor omm.com Newport Beach,…
To view the full exhibit click here

About EDWARDS LIFESCIENCES CORPORATION (NYSE:EW)

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. The Company conducts operations around the world and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.